[go: up one dir, main page]

GT200600077A - Imidazoles sustituidos con heterociclilamida - Google Patents

Imidazoles sustituidos con heterociclilamida

Info

Publication number
GT200600077A
GT200600077A GT200600077A GT200600077A GT200600077A GT 200600077 A GT200600077 A GT 200600077A GT 200600077 A GT200600077 A GT 200600077A GT 200600077 A GT200600077 A GT 200600077A GT 200600077 A GT200600077 A GT 200600077A
Authority
GT
Guatemala
Prior art keywords
imidazols
replaced
heterociclilamide
preparation
treatment
Prior art date
Application number
GT200600077A
Other languages
English (en)
Inventor
Holger Zimmermann
David Brueckner
Kerstin Henninger
Ulrich Rosentreter
Martin Hendrix
Joerg Keldenich
Dieter Lang
Martin Radtke
Daniela Paulsen
Armin Kern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600077A publication Critical patent/GT200600077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCIÓN SE REFIERE A IMIDAZOLES SUSTITUIDOS CON HETEROCICLILAMIDAS Y PROCEDIMIENTOS PARA SU PREPARCIÓN, SU USO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES ASÍ COMO SU USO PARA LA PREPARCIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, ESPECIALMENTE PARA EL USO COMO AGENTES ANTIVIRALES, ESPECIALMENTE CONTRA CITOMEGALOVIRUS.
GT200600077A 2005-02-23 2006-02-16 Imidazoles sustituidos con heterociclilamida GT200600077A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005008183A DE102005008183A1 (de) 2005-02-23 2005-02-23 Heterocyclylamid-substituierte Imidazole

Publications (1)

Publication Number Publication Date
GT200600077A true GT200600077A (es) 2006-10-03

Family

ID=36675125

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600077A GT200600077A (es) 2005-02-23 2006-02-16 Imidazoles sustituidos con heterociclilamida

Country Status (28)

Country Link
US (1) US7919489B2 (es)
EP (1) EP1853582B1 (es)
JP (1) JP5208522B2 (es)
KR (1) KR101276003B1 (es)
CN (1) CN101128455B (es)
AR (1) AR053141A1 (es)
AT (1) ATE446292T1 (es)
AU (1) AU2006218276C1 (es)
BR (1) BRPI0607995B8 (es)
CA (1) CA2598521C (es)
DE (2) DE102005008183A1 (es)
DK (1) DK1853582T3 (es)
ES (1) ES2333249T3 (es)
GT (1) GT200600077A (es)
HN (2) HN2006007774A (es)
IL (1) IL185050A (es)
MX (1) MX2007010308A (es)
MY (1) MY140543A (es)
NO (1) NO338997B1 (es)
NZ (1) NZ560811A (es)
PE (2) PE20100233A1 (es)
PL (1) PL1853582T3 (es)
PT (1) PT1853582E (es)
RU (1) RU2415851C2 (es)
TW (1) TWI388553B (es)
UY (1) UY29387A1 (es)
WO (1) WO2006089664A2 (es)
ZA (1) ZA200707412B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004015007A1 (de) 2004-03-26 2005-10-13 Bayer Healthcare Ag Substituierte Imidazole
DE102005008183A1 (de) 2005-02-23 2006-08-31 Bayer Healthcare Ag Heterocyclylamid-substituierte Imidazole
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
CN104610160A (zh) * 2013-11-04 2015-05-13 南京大学 含哌嗪环的5-硝基咪唑类衍生物及其制备与在抗菌药物中的应用
CN104016925B (zh) * 2014-06-17 2016-03-30 遵义医学院 4-烷基咪唑-2-羧酸的合成方法
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
CN116120238B (zh) * 2023-03-01 2023-09-22 山东梅奥华卫科技有限公司 一种咪唑衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
DE1019040T1 (de) * 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
CA2308428A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
PT1098885E (pt) * 1998-07-23 2005-01-31 Fujisawa Pharmaceutical Co Compostos de imidazole e sua utilizacao como inibidores da desaminase de adenosina
JP2002533301A (ja) 1998-12-09 2002-10-08 ワイス 置換フェニレンジアミン群を含む、複素環式カルボキサミド含有の、ヘルペスウイルスのチオ尿素インヒビター
DE10257358A1 (de) * 2002-12-09 2004-07-08 Bayer Healthcare Ag Substituierte Pyrrole
DE102004015007A1 (de) * 2004-03-26 2005-10-13 Bayer Healthcare Ag Substituierte Imidazole
US7326729B2 (en) * 2004-05-12 2008-02-05 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
DE102005008183A1 (de) 2005-02-23 2006-08-31 Bayer Healthcare Ag Heterocyclylamid-substituierte Imidazole

Also Published As

Publication number Publication date
HK1110857A1 (zh) 2008-07-25
ATE446292T1 (de) 2009-11-15
JP5208522B2 (ja) 2013-06-12
HN2010000128A (es) 2010-03-29
BRPI0607995B8 (pt) 2021-05-25
CA2598521A1 (en) 2006-08-31
MX2007010308A (es) 2007-10-17
ES2333249T3 (es) 2010-02-18
KR20080002772A (ko) 2008-01-04
IL185050A (en) 2013-01-31
HN2006007774A (es) 2010-03-29
EP1853582A2 (de) 2007-11-14
CN101128455A (zh) 2008-02-20
NO338997B1 (no) 2016-11-07
PE20061141A1 (es) 2006-12-29
NO20074780L (no) 2007-11-01
MY140543A (en) 2009-12-31
IL185050A0 (en) 2007-12-03
AU2006218276B2 (en) 2011-04-07
RU2007135277A (ru) 2009-03-27
RU2415851C2 (ru) 2011-04-10
PL1853582T3 (pl) 2010-03-31
US20080176859A1 (en) 2008-07-24
JP2008531508A (ja) 2008-08-14
PE20100233A1 (es) 2010-04-22
UY29387A1 (es) 2006-10-02
EP1853582B1 (de) 2009-10-21
BRPI0607995A2 (pt) 2009-10-27
ZA200707412B (en) 2008-12-31
AR053141A1 (es) 2007-04-25
WO2006089664A3 (de) 2006-11-02
TWI388553B (zh) 2013-03-11
DK1853582T3 (da) 2010-01-18
NZ560811A (en) 2010-07-30
TW200700411A (en) 2007-01-01
DE502006005182D1 (de) 2009-12-03
WO2006089664A2 (de) 2006-08-31
AU2006218276C1 (en) 2012-06-28
CA2598521C (en) 2012-11-27
AU2006218276A1 (en) 2006-08-31
BRPI0607995B1 (pt) 2019-07-16
US7919489B2 (en) 2011-04-05
PT1853582E (pt) 2009-11-13
CN101128455B (zh) 2013-01-16
DE102005008183A1 (de) 2006-08-31
KR101276003B1 (ko) 2013-06-20

Similar Documents

Publication Publication Date Title
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
HN2004000146A (es) Dihidroquinazolinas sustituidas
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
HN2005030779A (es) Nonadepsipeptidos acilados ii
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
UY29417A1 (es) Agentes endoparasiticidas
UY30135A1 (es) Quinolonas sustituidas iii
CU23662B7 (es) Imidazoles sustituidos con heterociclilamida
CL2008002116A1 (es) Composicion farmaceutica compuesta por la combinacion de 25 a 500 mg de lamotrigina y 0.5 a 20 mg de clonazepam; y uso para el control y tratamiento de enfermedades tales como trastornos convulsivos, sindromes epilepticos y enfermedades relacionadas.